Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Haemophilia treatment in 2030
View through CrossRef
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as well as dilemmas. Today, the issue of inhibitors overshadows the entire haemophilia community together with lack of treatment for large parts of the world's persons with haemophilia.AimsThe aim of this paper was to provide a perspective on haemophilia treatment in 2030 and its provenance.MethodsLiterature review on history, treatment of haemophilia today as well as of emerging therapies give a base for the author's opinion on haemophilia treatment in 2030.ResultsDevelopment of haemophilia treatment has virtually exploded during the last decade and a number of new clotting factor concentrates and alternative approaches are in the pipeline.ConclusionThe collection of treatment resources that we can see on the horizon gives hope that each person with haemophilia will get the care needed in 2030. The products used will be directed by individual needs and tailored to regional and local situations.
Title: Haemophilia treatment in 2030
Description:
IntroductionLooking into the future is difficult and sometimes hazardous.
A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as well as dilemmas.
Today, the issue of inhibitors overshadows the entire haemophilia community together with lack of treatment for large parts of the world's persons with haemophilia.
AimsThe aim of this paper was to provide a perspective on haemophilia treatment in 2030 and its provenance.
MethodsLiterature review on history, treatment of haemophilia today as well as of emerging therapies give a base for the author's opinion on haemophilia treatment in 2030.
ResultsDevelopment of haemophilia treatment has virtually exploded during the last decade and a number of new clotting factor concentrates and alternative approaches are in the pipeline.
ConclusionThe collection of treatment resources that we can see on the horizon gives hope that each person with haemophilia will get the care needed in 2030.
The products used will be directed by individual needs and tailored to regional and local situations.
Related Results
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
Normalisation of Haemostasis in Haemophilia A
Normalisation of Haemostasis in Haemophilia A
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, ...
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
IntroductionCoagulation products have allowed patients with severe haemophilia to lead a normal life. This is, however, only true for patients who received an early diagnosis and c...
Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
AbstractObjectiveTo analyse the demographic, clinical and laboratory data of Beninese patients with haemophilia.MethodA prospective survey was conducted in three different hospital...
Hemgenix as First Gene Therapy for Treatment of Haemophilia B
Hemgenix as First Gene Therapy for Treatment of Haemophilia B
We know about haemophilia B is an inheritable bleeding complaint performing from missing or inadequate situations of blood clotting Factor IX, a protein demanded to produce blood c...
Sexual expression, fulfilment and haemophilia: reflections from the 16th Australian and New Zealand Haemophilia Conference
Sexual expression, fulfilment and haemophilia: reflections from the 16th Australian and New Zealand Haemophilia Conference
Summary. Following a presentation given at the 16th Australian and New Zealand Haemophilia Conference; Enjoying your sex life: Issues and solutions for men with physical impairmen...
Utilization of Fresh Frozen Plasma and Cryoprecipitate in Factor VIII and Factor IX Deficient Hemophilia Patient
Utilization of Fresh Frozen Plasma and Cryoprecipitate in Factor VIII and Factor IX Deficient Hemophilia Patient
Haemophilia is one of the most common causes of inherited bleeding disorder resulting from deficiency of coagulation factor VIII or factor IX. Ideally, replacement should be done w...
The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery
The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery
Summary. While a majority of affected infants of haemophilia carriers who deliver vaginally do not suffer a head bleed, the outcome of labour cannot be predicted. A planned vagina...